Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases
- 1 August 2003
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 49 (2) , 281-287
- https://doi.org/10.1067/s0190-9622(03)00855-7
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Rituximab: Mechanism of action and resistanceSeminars in Oncology, 2002
- Rituximab in combination with CHOP or fludarabine in low-grade lymphomaSeminars in Oncology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-TreatmentJournal of Clinical Oncology, 2000
- Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphomaAnnals of Oncology, 1999
- Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of RituximabJournal of Clinical Oncology, 1999
- Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP ChemotherapyJournal of Clinical Oncology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994